Covid-19 vaccine: Delhiites to wait longer for Sputnik V; Roll-out delayed

By: |
June 20, 2021 1:47 PM

A spokesperson of Apollo Hospitals said the facility in Delhi will tentatively start administering the two-dose vaccine by June 25.

sputnik, vaccination in Delhi, covid -19 vaccine, russian vaccine sputnik, Russia's Gamaleya National Research Institute of Epidemiology and Microbiology, Apollo Hospitals, Madhukar Rainbow Children's Hospital,An official had earlier said the hospital would start giving Sputnik V jabs by June 20.

The roll out of Russian COVID-19 vaccine Sputnik V at Indraprastha Apollo and Madhukar Rainbow Children’s Hospital in Delhi has been delayed for some days, officials said on Sunday. A spokesperson of Apollo Hospitals said the facility in Delhi will tentatively start administering the two-dose vaccine by June 25.

An official had earlier said the hospital would start giving Sputnik V jabs by June 20 According to an official of Madhukar Rainbow Children’s Hospital, there is a delay on the part of the suppliers. “We are expecting (roll out) next week,” he said.

Fortis Healthcare, which had said it would make Sputnik V available at its Gurgaon and Mohali hospitals from Saturday, also has not started administering the Russian vaccine so far. “The roll out did not happen on Saturday. We expect there will be some clarity on Monday,” an official said.

The Centre has fixed the price of the vaccine at Rs 1,145 per dose. The maximum price of Covishield for private COVID-19 Vaccination Centres (CVCs) has been fixed at Rs 780 per dose, while that of Covaxin is Rs 1,410 per dose. Russia’s Gamaleya National Research Institute of Epidemiology and Microbiology has developed Sputnik V and the Russian Direct Investment Fund (RDIF) is marketing it globally.

Hyderabad-based Dr Reddy’s Laboratories, the marketing partner for the vaccine in the country, has been importing the shots from Russia. Over a period of time, the vaccine is also going to be manufactured in India. Sputnik V uses two different viruses that cause the common cold (adenovirus) in humans. It employs a different vector for each of the two shots, given 21 days apart.

According to Gamaleya and the RDIF, Sputnik V has demonstrated an efficacy rate of 92 per cent.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Chinese President Xi promises to provide 2 bn doses of COVID-19 vaccines globally
2Covid-19: India in talks with various countries for mutual recognition of vaccine certifications
3Not prosecuting good samaritans for O2 distribution: Delhi drug controller to HC